Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
复制标题
DOI：
10.1016/s0140-6736(08)61525-1
复制
发表时间：
2008-11-01
期刊：
影响因子：
168.9
通讯作者：
Larsen, Thomas Meinert
中科院分区：
文献类型：
--
作者：
Astrup, Arne;Madsbad, Sten;Larsen, Thomas Meinert
背景减肥药在6个月内仅比饮食和安慰剂多减重3-5公斤，需要更有效的肥胖症药物治疗。我们评估了去甲肾上腺素、多巴胺和5-羟色胺突触前摄取的抑制剂--替芬辛在肥胖患者中的有效性和安全性。方法我们在5个丹麦肥胖管理中心进行了一项II期随机、双盲、安慰剂对照试验。经过两周的磨合期，203名肥胖患者(体重指数30-
Background Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet arid placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity.Methods We undertook a phase II, randomised, double-blind, placebo-co n trolled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients (body-mass index 30-